Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Bedaquiline and Delamanid in MDR-TB
NCT02583048Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of bedaquiline, delamanid in pulmonary tuberculosis (TB), sponsored by National Institute of Allergy and Infectious Diseases. Started Aug 2016; status: completed.
02
Drugs
bedaquilinedelamanid
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT02583048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583048.